Abstract
This study maps the comparative protein-protein interaction (PPI) landscape of three pathogenic betacoronaviruses: SARS-CoV-1, SARS-CoV-2, and MERS-CoV. By identifying conserved host proteins—termed "dependency factors"—that these viruses hijack for replication, researchers have uncovered stable therapeutic targets less prone to viral mutational escape. Functional genomic screens and structural analysis identified key interactions, such as the suppression of innate immunity by viral ORF9b via the mitochondrial receptor TOM70. Furthermore, the study identifies PGES-2 and Sigma-1 receptors as druggable host factors. Retrospective clinical analysis of over 700,000 patients suggests that existing medications targeting these factors, including indomethacin and typical antipsychotics, are associated with improved clinical outcomes in COVID-19 patients.
Introduction
The rapid mutation of viral proteins often leads to the development of drug resistance, limiting the long-term efficacy of direct-acting antivirals. To address this, researchers have turned to the "host-pathogen interactome," focusing on the physical interactions between viral proteins and the more slowly evolving human host machinery. By identifying host factors essential for viral replication (dependency factors) that are shared across different betacoronaviruses, it is possible to develop broad-spectrum, "future-proof" therapeutic strategies.
Methods
The researchers employed a multi-disciplinary approach to map and validate the betacoronavirus interactome:
- Interactome Mapping: Mass spectrometry was used to identify host proteins binding to tagged viral proteins from SARS-CoV-1, SARS-CoV-2, and MERS-CoV in HEK293T cells.
- Functional Screening: siRNA and CRISPR-Cas9 genetic screens in lung and gut cell lines identified host proteins whose absence significantly reduced viral replication.
- Structural Biology: Cryo-electron microscopy (CryoEM) characterized the physical interface between specific viral and host proteins, notably the ORF9b-TOM70 complex.
- Clinical Validation: A retrospective analysis of medical billing records for 738,933 COVID-19 patients was conducted to evaluate the real-world impact of drugs targeting the identified host factors.
Key Insights and Results
Conservation of Viral-Host Interactions
The study revealed that while viral sequences diverge, the functional groups of host proteins they interact with remain highly conserved. SARS-CoV-1 and SARS-CoV-2 exhibit more similar interaction profiles compared to MERS-CoV. A critical finding was the identification of 12 host proteins that interact with the viral protein NSP7 across multiple coronaviruses.
Mechanisms of Immune Evasion and Druggable Targets
A major discovery involved the viral protein ORF9b, which binds to TOM70, a mitochondrial import receptor. This interaction disrupts the IFN-β signaling pathway, effectively "short-circuiting" the host's innate immune response.
Additionally, the study highlighted two specific host factors with existing FDA-approved inhibitors:
- PGES-2: Involved in prostaglandin synthesis and inhibited by the anti-inflammatory drug indomethacin.
- Sigma-1 Receptor: A target for typical antipsychotic medications.
Clinical Outcomes
Retrospective analysis provided promising evidence for drug repurposing:
- Indomethacin: Outpatients taking indomethacin showed a significantly lower risk of hospitalization, with an odds ratio (OR) of 0.33 (95% CI: 0.03–3.19).
- Antipsychotics: Patients on typical antipsychotics targeting the Sigma-1 receptor demonstrated a reduced need for mechanical ventilation (OR 0.46, 95% CI: 0.23–0.93).
- ACE2 Dominance: Genetic screens confirmed that ACE2 remains the primary entry receptor, as its knockout almost entirely abolished virus production.
Discussion and Limitations
While these findings identify potent new avenues for treatment, several limitations remain. The clinical data is retrospective and requires validation through prospective randomized controlled trials. Furthermore, the timing of treatment is critical; for instance, interferon-based therapies may only be effective during the early stages of infection. Despite these challenges, targeting conserved host dependency factors represents a robust strategy for managing current and future coronavirus pandemics.
Summary updated